The influence of the pharmacokinetics and bioavailability of cyclo-L-propylglycine to the manifestation of its main pharmacological effects in experimental animals
https://doi.org/10.37489/2587-7836-2020-3-25-29
Abstract
In the article presented the results of research of the influence pharmacokinetics, bioavailability for CNS cyclo-L-prolylglycine to the manifestation of its main pharmacological effects in experimental animals.
About the Authors
S. S. Boyko
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Boyko Svetlana S., PhD in Biology, Senior Researcher of laboratory
pharmacokinetics
SPIN code: 4176-8921
K. N. Koljasnikova
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Koliasnikova Ksenia N. , PhD in Biology, Research scientist of laboratory of peptide bioregulators of the Department of drug
chemistry
SPIN code: 5682-2035
V. P. Zherdev
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Zherdev Vladimir P. , D. Sci. in Medicine, Professor, Head of laboratory pharmacokinetics
SPIN code: 2213-9592
References
1. Boyko SS, Zherdev VP, Gudasheva ТA et al. Pharmacokinetics of dipeptide analog pyracetame wich nootropic activity GWS-111 and its main metabolites. Russian Journal of Experimental and Clinical Pharmacology.1997;72(2):3-6. (In Russ).
2. Boyko SS, Zherdev VP, Korotkov SA at al. Pharmacokinetics of new potencial dipeptide nootrope GWS-111 and its main metabolites in rat brain. Khimiko-Farmatsevicheskiy Zhurnal.2001;35(9):11-13. (In Russ).] DOI:10.1023/A^10140824082406443.
3. Gudasheva TA, Boyko SS, Akparov VKh et al. Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. FEBS Lett.1996;391(1-2): 149-152. DOI 10.1016/0014-5793(9600722-311.
4. Gudasheva TA, Boyko SS, Ostrovskaya RU et al. The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. Eur J Drug Metab Pharmacokinet. 1997;22(3):245-52. DOI: 1007/BF03189814.
5. Gudasheva ТA, Ostrovskaya RU, Trofimov SS et al. New endogenous dipetide cycloprolylglicine is similar to piracetam by its mnemotropic selectivity. Bulletin of experimental biology and medicine. 1999;128 (10):411-413. (In Russ).]
6. Kolyasnikova KN, Gudasheva TA, Nazarova GA et al. Similarity of cycloprolylglycine to piracetam in antigypoxic and neuroprotective effects. Russian Journal of Experimental and Clinical Pharmacology. 2012;75(9): 3-6. (In Russ).] DOI: 10.30906/0869-2092-2012-75-9-3-6
7. Nikolaev SV, Logvinov IO, Antipov et al. Neuroprotective effect of cyclo-L-prolylglycine on models of neuronal cells damage in vitro. Pharmacokinetics and Pharmacodynamics.2017;(3):26-29. (In Russ).]
8. Kolyasnikova KN. Izuchenie mekhanizma deistviya neiropeptida tsikloprolilglitsina i vozmozhnost' sozdaniya na etoi osnove novykh nootropnykh soedinenii. [dissertation]. Moscow; 2018. (In Russ).] Доступно по: https://www.academpharm.ru/dissertation/defence/kolyasnikova. Ссылка активна на 12.12.2020.
9. Guan J. Insulin-like growth factor-1 and its derivatives potential pharmaceutical application for ischemic brain injury. Recent Pat CNS Drug Discov.2008;3(2):112-27. DOI:10.2174/157488908784534630
10. Ostrovskaya RU, Lyapina LA, Pastorova VE et al. A multicomponent antithrombotic effect of the neuroprotector prolyl-containing dipeptide GVS-111 and its metabolite cyclo-L-prolylglycine. Russian Journal of Experimental and Clinical pharmacology.2002;2:34-37. (In Russ).] DOI: 10.30906/0869-2092-2002-65-2-34-37.
11. Boiko SS, Gudasheva TA, Vichuzhanin MV et al. Regional and subcellular localization of cycloprolylglycine in the rat brain. Bulletin of Experimental Biology and Medicine.2010;149(6):709-711. (In Russ).]
12. Seredenin SB, Gudasheva TA, Boiko SS et al. Endogenous dipeptide cycloprolylglycine shows selective anxiolytic activity in animals with manifest fear reaction. Bulletin of Experimental Biology and Medicine. 2002;133(4):360-362. (In Russ).]
13. Zherdev VP, Boyko SS, Kolyasnikova KN. The relationship between the content of the potential psychopharmacological agent cyclo-L- prolylglycine in the brain of experimental animals and its antihypoxic effect. Pharmacokinetics and pharmacodynamics.2020;(1):25-29 (In Russ).] DOI: 10/37489/2587-7836-2020-1-25-29.
14. Abdullina AA, Vasilyeva EV, Kondrakhin EA, Kovalev GI. Participation of serotonin, glutamate, and GABA receptors in the manifestation of antidepressive-like effect of cycloprolylglycine. Neurochemistry. 2019;36(3):219-228 (In Russ).] DOI: 10.1134/S1027813319030026.
15. Abdullina AA, Vasilyeva EV, Kudrin VS et al. The effects of cycloprolylglycine and its analogues on brain monoaminergic systems in BALB/c mice. Pharmacokinetics and pharmacodynamics.2020;(1):3-10. (In Russ).] DOI: 10.37489/2587-7836-2020-1-3-10.
Review
For citations:
Boyko S.S., Koljasnikova K.N., Zherdev V.P. The influence of the pharmacokinetics and bioavailability of cyclo-L-propylglycine to the manifestation of its main pharmacological effects in experimental animals. Pharmacokinetics and Pharmacodynamics. 2020;(3):25-29. (In Russ.) https://doi.org/10.37489/2587-7836-2020-3-25-29
Views:
368
Email this article 